Vaxcyte Doses First Participants in the OPUS Phase 3, …
3 days ago · Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in …
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31
2 days ago · SAN CARLOS, Calif. - Vaxcyte, Inc. (NASDAQ:PCVX) has dosed the first participants in its Phase 3 OPUS trial evaluating VAX-31, a 31-valent pneumococcal conjugate …
Vaxcyte Advances VAX-31 Infant Study to Stage 2 Following
Feb 5, 2025 · Vaxcyte advances VAX-31 infant study to Stage 2, aiming for enhanced pneumococcal disease protection. Vaxcyte, Inc. announced that it has progressed to Stage 2 …
Vaxcyte Provides Positive Regulatory Updates on VAX-31
Nov 12, 2024 · VAX-31, the broadest-spectrum PCV candidate in the clinic, is a potentially best-in-class investigational 31-valent pneumococcal conjugate vaccine (PCV) candidate being …
Vaxcyte Advances To Stage 2 In Phase 2 Study Of VAX-31 For …
Feb 6, 2025 · Vaxcyte, Inc. (PCVX) has announced the progression to Stage 2 of its ongoing Phase 2 study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine or PCV, in …
Vaxcyte Doses First Participants in the OPUS Phase 3 ... - BioSpace
2 days ago · Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in …
FDA clears investigational NDA for VAX-31 to prevent invasive ...
Nov 12, 2024 · VAX-31 (Vaxcyte), an infant and adult investigational 31-valent pneumococcal conjugate vaccine (PCV) candidate to prevent invasive pneumococcal disease (IPD), has …
Vaxcyte reports positive topline results in study of VAX-31
Sep 3, 2024 · Vaxcyte announced in September 2024 that its Phase I/II study of VAX-31, the 31-valent pneumococcal conjugate vaccine (PCV), has produced positive topline results. The …
Homepage - Vaxcyte
Our PCV franchise, comprising VAX-31 and VAX-24, has the potential to improve upon existing pneumococcal vaccines, setting a new standard-of-care and raising the bar for immunogenicity.
Vaxcyte Doses First Participants in the OPUS Phase 3, …
2 days ago · Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in …